Objectives
To establish the efficacy and safety of botulinum toxin aimed at improving UOS dysfunction in people with swallowing difficulties (dysphagia) associated with non progressive and progressive neurological disease.
Search methods
We searched the following electronic databases for published trials: the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (1950 to 2013); EMBASE (1980 to 2013); AMED (Allied and Complementary Medicine) 1941 to 2013; CINAHL (Cumulative Index to Nursing and Allied Health Literature) 1937 to 2013. We also searched major clinical trials registers: CCT (http:/ /www.controlled-trials.com); Clinical Trials (http://www.clinicaltrials.gov); Chinese Clinical Trial Register (www.chictr.org);ACTR ( http://www.actr.org.au/. We examined the reference lists from all potentially relevant studies to identify further relevant trials. We handsearched published abstracts of conference proceedings from both the Dysphagia Research Society and also the European Society 
Selection criteria
Only randomised controlled trials (RCTs) were included
Data collection and analysis
Independent searches were completed by JR, AM, MC and MW, Two review authors (JR and MW) independently inspected titles, abstracts and key words identified from the literature search.
Main results
No randomised controlled studies were retrieved. Studies were excluded mainly on the basis of trial design.
Authors' conclusions
It was not possible to reach a conclusion on the efficacy and safety of botulinum toxin as an intervention for people with UOS dysfunction and neurological disease.
There is insufficient evidence to inform clinical practice. Directions for future research are provided.
P L A I N L A N G U A G E S U M M A R Y [Summary title]
[ Many people have problems swallowing because of an impairment of the upper oesophageal sphincter (UOS) -a high pressure zone within the tube that carries food from the mouth to the stomach. Many people with neurological conditions such as stroke, traumatic brain injury, Parkinson's disease, multiple sclerosis can have UOS imp[airment. This results in difficulty swallowing food and liquids, resulting in choking and food enetrring into the lungs ( aspiration). This has serious consequences for the patient and can cause dehydration, malnutrition and aspiration pneumonia. The person's quality of life can be affected as they are unable to have food or liquids safely by mouth. Tube feeding and hospitalisation is often required.
Many interventions are used to imprive UOS function. These include surgery, medications, botulinum toxin, rehabilitation exercises, diet modification and other compensatory techniques.
There is no clear consensus on whether botulinum toxin is safe and effective in managing UOS dysfunction in people with neurological conditions. This makes it hard to decide which intervention will be safest and most effective to improve swallowing and quality of life.
Only randomised controlled trials were included in this review. Trials were sought through electronic searches of databases, searches of clinical trials registers, peer reviewed journals, published conference proceedings and reference lists of relevant articles.
No trials that met the inclusion criteria for the review were found.
There is insufficient evidence to support the use of botulinum toxin to improve swallowing in people with UOS dysfunction and neurological disease. The lack of trials does not suggest that this interventions is ineffective.
Adequately powered well designed trials are required. In addition to using sensitive measures looking at change in swallow function, measures are needed that examine client and carer satisfaction, changes in quality of life, psychological well being and in unwanted symptoms associated with the intervention.
Summary text]
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Description of the condition
The upper oesophageal sphincter (UOS) or pharyngo-oesophageal segment (POS) is defined physiologically as a high-pressure zone forming a barrier between the pharynx and the oesophagus. This obstruction prevents diversion of air into the oesophagus during inspiration. It also protects the airway from any retrograde passage of material refluxed from the oesophagus or stomach (Singh 2005) . Three muscles contribute to form the UOS: the cricopharyngeus (CP) muscle; the most inferior muscle fibres of the inferior pharyngeal constrictor muscle; and the most superior portion of the longitudinal oesophageal muscular fibres (Sivarao 2000). First described by Valsalva in 1717, the cricopharyngeus is the main component of the UOS. Arising from the lateral borders of the cricoid lamina, it is a C-shaped muscle which forms a sling around the wall of the superior aspect of the cervical oesophagus (Sivarao 2000) . At rest, the sphincter has a slit-like configuration, with the CP making up the lateral and posterior walls and the cricoid lamina positioned anteriorly. The CP is bordered superiorly by the inferior constrictor muscle and merges inferiorly with the muscular layers of the cervical oesophagus. While the UOS is normally in a tonic state of contraction, it relaxes intermittently to allow transsphincteric flow of fluid or gas during antegrade (e.g. swallowing) and retrograde (e.g. emesis or belching) events (Cook 2000) . In order for the swallow to be safe and efficient, the UOS needs to open adequately to allow material to pass from the pharynx into the oesophagus. Adequate UOS opening is critical to safe and efficient swallowing due to the close proximity between the UOS and the airway entrance. Manofluoroscopic studies have demonstrated that UOS opening occurs by a combination of CP relaxation, anterior and superior hyolaryngeal excursion and bolus pressure (Cook 1989). In the initial relaxation phase, there is vagal inhibition of the tonic contraction of the CP muscle, as observed by needle electromyography (EMG) (Ertekin 2002). This precedes UOS opening by 200 milliseconds and lasts 300 to 600 milliseconds. In the second phase; UOS opening occurs via the biomechanics of hyolaryngeal excursion (Cook 1989). Suprahyoid muscles (geniohyoid, mylohyoid, stylohyoid, hyoglossus and the anterior belly of the digastric) contract, causing the hyoid bone to be pulled both anteriorly and superiorly. This movement, paired with contraction of the thyrohyoid, an infrahyoid muscle which is the main connection between the hyoid bone and the larynx, pulls the laryngeal complex in a superior and anterior direction. As the UOS is connected to the laryngeal complex via CP muscle attachment to the cricoid cartilage, the anterior portion of the UOS is pulled open. The UOS assumes an oval cross section and is raised 2 to 2.5 cm in an orad direction. In the third distension phase, pressure applied by the weight and volume of the onrushing bolus distends the lumen of the UOS. This distension collapses in the fourth phase as the bolus passes through the sphincter. Finally, in the fifth phase the UOS closes as the cricopharyngeus actively contracts (Cook 1989) . UOS dysfunction during swallowing has been reported in numerous acute and progressive neurological conditions including, but not limited to, brainstem stroke (Bian 2009), motor neuron disease ( 
Description of the intervention
While there are 7 different subtypes of botulinum toxin, Botulinum toxin A (BTA) is the most commonly used sub type in the treatment of UOS dysfunction. While botulinum toxin B (BTB) is used to treat conditions such as cervical dystonia and drooling, particularly when patients have developed a resistance to BTA (Costa 2005), it is used less widely in clinical practice to treat UOS dysfunction. BTA formulations available include Botox® (Allergan Inc.) and Dysport® (Ipsen Ltd). Both products differ in terms of molecular structure, manufacturing processes and use different methods for determining biological activity (Heinen 2006). One unit of Botox® is estimated to be comparable to three to four units of Dysport® (Fuster Torres 2007) Schneider 1994 initially described the use of BTA for the treatment of CP dysphagia. This resulted in a temporary relaxation of the CP musculature and improved opening of the UOS during swallowing. Seventy per cent of participants had more efficient bolus transport into the oesophagus during swallowing and reduced aspiration events. The intervention usually brings improvement in deglutition but most patients require reinjection in three to five months (Krause 2008). Also, reported side effects include inadvertent injection outside the cricopharyngeus which may result in temporary paralysis of the laryngeal musculature, causing dysphonia and, rarely, aspiration. In cases where there is uncertainty regarding the diagnosis of impaired UOS dysphagia, a positive response to a trial of botulinum toxin treatment can suggest candidacy for cricopharyngeal myotomy (Krause 2008). Since this initial 1994 study, cricopharyngeal BTA injection has been reported in over 200 patients with dysphagia of varying aetiologies with success rates between 43% and 100% (Alberty 2000; Alfonso 2010; Chiu 2004;Krause 2008). However, studies have recruited heterogeneous diagnostic groups and candidacy criteria for BTA injections vary considerably across studies. Additionally, BTA brand and dosage (2.5 to 50 units Botox®; 60-360 units Dysport®); injection site, technique (rigid endoscopy, flexi-ble endoscopy, transcervical with EMG, transcervical CT-guided) and outcome measure evaluations (videofluoroscopy, manometry, EMG), among other factors, have differed across studies. This has led to confusion regarding the usefulness of this technique.
How the intervention might work
Botulinum toxin is a neurotoxin that inhibits presynaptic acetylcholine release and hence chemically denervates the motor endplate. Once injected, botulinum toxin binds rapidly to presynaptic cholinergic nerve terminals, impairing the release of acetylcholine (chemical denervation) at the neuromuscular junction. This results in a temporary dose-related weakness or reversible palsy of the innervated muscle. Therapeutic effects are usually seen with three days of the injection. Peripheral neuronal sprouting prevents the effects from being permanent. Reports to date suggest that effects last from two to up to twenty four months (Kim 2006; Masiero 2006) . BTA has been used effectively in the past for the management of a number of hyperkinetic disorders (e.g. blepharospasm, torticollis, spasmodic dysphonia) with good results and limited side effects (Jankovic 1991). In more recent times, its use has expanded to treat UOS dysfunction in neurogenic dysphagia ( 
Why it is important to do this review
Clinicians working with people with dysphagia secondary to UOS dysfunction as a result of acute or progressive neurological disease have difficulty determining the efficacy of botulinum toxin injections to treat dysphagia in individuals with neurogenic dysphagia. The most effective formulation, sites for injection, the optimum dosage, the method of delivery (endoscopic or transcutaneous), and the length of time before effects wear off are as yet undetermined. There are currently no systematic reviews examining the efficacy of botulinum toxin to treat UOS dysfunction in acute or progressive neurological populations, despite it being a topical issue. Given the fact that botulinum toxin is being used clinically to treat UOS dysfunction with limited evidence base, as well as the adverse events associated with the intervention, a systematic review of the evidence is required in this area. Evidence is required not only from a clinical perspective, but also to identify specific direction for future clinical trials and intervention studies in the area. 2. To provide the best evidence to inform clinical practice.
O B J E C T I V E S
3. To assist with future research planning.
M E T H O D S Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) were included in the review. A RCT is defined as an experiment in which an intervention (e.g. botulinum toxin) and one control treatment or no treatment are compared by being randomly allocated to participants. In most trials one intervention is assigned to each individual but sometimes assignment is to defined groups of individuals or interventions are assigned within individuals (for example, in different orders or to different parts of the body). Crossover trials would only be included if the washout period of the botulinum toxin was known. We did not apply any language limits on published studies or date restrictions on trials.
Types of participants
We planned to include all trials involving adults (18 years +) both male and female with oro-pharyngeal dysphagia secondary to acute (e.g. stroke, traumatic brain injury (TBI) non progressive and progressive neurological disease (e.g. Parkinsons disease, motor neuron disease, multiple sclerosis). We excluded trials that include participants with congenital neurological conditions (e.g. cerebral palsy) as dysphagia in these diagnostic groups is multifactorial. We excluded trials that included participants with independent or co-morbid non-neurological causes of dysphagia (e.g head and neck cancer, tracheostomy, oesophageal disease, structural abnormality such as pharyngeal or oesophageal diverticulum).
Types of interventions
We l considered all trials that involved delivery of all sub types of botulinum toxin injections into the upper oesophageal sphincter either endoscopically or transcutaneously. We included trials that involve all dosages and types (i.e. all commercial brands) of botulinum toxin). We considered reports of trials that included all injection sites within the UOS. We included studies which combined botulinum toxin injections with other dysphagia interventions that were provided in the intervention group, as long as all methods except for botulinum toxin injections were provided to both treatment and control groups and the specific effects of the botulinum toxin could be reliably determined. Comparisons
• Botulinum toxin versus no intervention • Botulinum toxin versus placebo • Botulinum toxin versus other intervention (i.e. traditional dysphagia rehabilitation)
• Botulinum toxin and traditional rehabilitation approach versus traditional rehabilitation approach (where traditional rehabilitation is identical in both groups)
Types of outcome measures
Binary outcomes were reported for all primary and secondary outcomes.
Primary outcomes
1. Positive change to oral intake status (Yes/No). 2. Reduction or elimination of aspiration or laryngeal penetration on food and/or fluids as rated on objective assessment (videofluoroscopy, fibreoptic examination of swallowing safety (FEES) (Yes/No).
3. Adverse events including increase in swallowing problems, compromised medical health, negative psychological consequences, negative social consequences, hospitalisation, death (Yes/No).
4. Client and/or carer satisfaction with intervention (Yes/No).
Secondary outcomes
1. Reduction or elimination of residue in the valleculae and/or pyriform sinus/ post swallow (Yes/No).
2. Positive change in quality of life (Yes/No). Regarding follow up of intervention effects, three time frames were considered: immediate (< one month) medium term (one to six months) and long term (> six months). Three time points were included to ensure that the long-lasting effects of botulinum toxin are captured.
Search methods for identification of studies Electronic searches
We searched the following bibliographic databases for published trials:
• The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library (last update) (Appendix 1);
• Ovid MEDLINE (1950 to 2013) (Appendix 2);
• Elsevier EMBASE (1980 to 2013) (Appendix 3); We searched major clinical trials registers:
• CCT (http://www.controlled-trials.com);
• Clinical Trials (http://www.clinicaltrials.gov); • Chinese Clinical Trial Register (www.chictr.org); • ACTR (http://www.actr.org.au/). The search strategy was developed for Ovid MEDLINE and translated for use on CENTRAL, EMBASE, AMED and CINAHL databases. We searched for articles with combinations of subject headings and key words relating to Botulinum toxin; and upper oesophageal sphincter; and dysphagia or deglutition or swallowing. We did not apply language limits and used the Cochrane Highly Sensitive Search Strategy for identifying randomised controlled trials in Ovid MEDLINE.
Searching other resources
We scanned the reference lists from all included studies to identify further relevant trials. We handsearched published abstracts of conference proceedings from both the Dysphagia Research Society and also the European Society of Swallowing Disorders (both published in Dysphagia). Digestive Disease Week (published in Gastroenterology) were also handsearched. Additionally, we searched ProQuest Dissertations & Theses for dissertation abstracts.
Data collection and analysis
Selection of studies
Two review authors (JR and MW) independently inspected titles, abstracts and key words identified from the literature search. Duplicate items were removed. The results of the literature search were categorised as 'potentially relevant', 'relevant 'and 'not relevant'. If it was unclear from titles and abstracts whether a study should be included, then we obtained copies of trials for further identification. We resolved any disagreement on selection of studies by consensus discussion. We listed those studies excluded in the Characteristics of excluded studies table.
Data extraction and management
A data extraction form was prepared for data extraction . Two review authors (JR and MW) planned to independently extract details of all included studies and where practicable, to contact study authors for incomplete details or missing data. It was planned that a third review author would extract data from a random sample of 20% of included studies.
Assessment of risk of bias in included studies
It was planned that two review authors would independently assess risk of bias in each included study. addressing the following issues which may be associated with biased estimates of treatment effect: sequence generation, allocation sequence concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting and other potential threats to validity (Higgins 2011). rsist.
Measures of treatment effect
we planned to carry out a meta-analyses of primary and secondary end pointsusing risk ratio (RR) and 95% confidence intervals (CI) for the analysis of dichotomous outcomes, and mean difference (MD) or standardized mean differences (SMD) and 95% confidence intervals (CI) for continuous outcomes.
Unit of analysis issues
To make sure the analysis matched the level of randomisation, we planned to identify the numerous variations on the designs of included studies (simple parallel group design, cluster-randomised trial, repeated measurements, recurring events, etc). As this is a review of a pharmaceutical procedure, we included both cluster-randomised and individually-randomised trials. If cluster-randomised trials were included and data analysed appropriately, analysis using the Generic Inverse Variance method would be used. Where the same patient was included more than once only the first episode of treatment would l be included and if patients have been allowed to cross over into the other arm, the data will beanalysed strictly by intention-to-treat (ITT) analysis. We contacted original authors whenever necessary and sought input from the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group editorial base for analysis issues involving any included trials with multiple treatment groups, and cluster-randomised designs.
Dealing with missing data
In the event of missing data, we agreed to contact the original trial authors to obtain this data or to seek clarification. Alternatively, we would perform a sensitivity analysis and address the potential impact of missing data on the findings of the review in the 'Discussion' section, as recommended by theCochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
Heterogeneity tests were planned using a standard Chi² test (significance at P < 0.1) or an I² statistic (> 75%). If there was evidence of heterogeneity, we would explore which factor caused it and perform subgroup analysis according to the possible reasons.
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Assessment of reporting biases
It was planned to report biases (publication bias, time lag bias, duplicate publication bias, location bias, citation bias, language bias or outcome-reporting bias) and minimise reporting bias through a comprehensive search for studies, inclusion of unpublished studies and use of trial registries, evaluating this bias using funnel plot asymmetry testing, if necessary.
Data synthesis
A meta-analysis for all randomised trials included in the review was planned, considering all the outcomes listed for data synthesis, with a random-effects model for the primary analysis, then use the fixed-effect model as a sensitivity analysis to check that results were robust regardless of which method is chosen.
Subgroup analysis and investigation of heterogeneity
We planned to l conduct a subgroup analysis focusing on the following:
• endoscopic versus transcutaneous botulinum toxin injections;
• site of injections; • needle used;
• botox type and formulation;
• dosage of botox.
If substantial heterogeneity (Chi² test P< 0.1 or an I² >50%) existed between studies for the primary outcome (i.e. aspiration/ penetration and oral intake), we would explore the reasons for heterogeneity; such as dysphagia severity, age and neurological diagnosis.
Sensitivity analysis
We planned to undertake sensitivity analysis to explore the potential influences on effect size. If heterogeneity resulted from low quality trials, we would exclude the lowest quality trials from this review.
R E S U L T S
Description of studies
See Characteristics of excluded studies.
Results of the search
In October 2012 and again in March 2013, searches were carried out according to the protocol. No randomised controlled trials were identified. Seventeen non randomised studies were retrieved.
Included studies
No included studies
Excluded studies
Seventeen studies were excluded following retrieval of full text.
Risk of bias in included studies
No eligible studies retrieved
Allocation
Blinding
Incomplete outcome data
Selective reporting
Other potential sources of bias
No studies retrieved
Effects of interventions
There is no strong evidence to support the use of botulinum toxin to improve UOS dysfunction in people with neurogenic dysphagia. However, non randomised studies suggest.....
D I S C U S S I O N
Summary of main results
No RCTs were retrieved in this review, Therefore, no conclusions can be reached on the efficacy and safety of botulinum toxin in the treatment of UOS dysfunction and dysphagia in adults with neurological disease. There is a growing use internationally of botulinum toxin to treat neurogenic dysphagia. Despite this, there is a lack of methodologically sound evidence to demonstrate the efficacy of this intervention. Specifically, no randomised control F o r P r e v i e w O n l y trials were found which investigate the use of botulinum toxin to treat dysphagia in adult neurological populations. The authors therefore cannot conclude at this time regarding this intervention.
Overall completeness and applicability of evidence
The lack of RCTs does not suggest that this intervention is ineffective but rather that RCTs are required on this intervention with this population. Despite the increasing popularity of botulinum toxin as an intervention for UOS dysfunction there is no evidence based consensus on the population of adults with UOS dysfunction most suited to this intervention, the differences between products available, whether BTA is preferable to BTB in some populations, the site most suited for injection, the preparation of the solution, calculations of ideal dosages, maximum dosage allowed, the safest method of delivery (calibre of needle, number of injection sites etc.), the use of general anaesthesia versus conscious sedation etc.
Quality of the evidence
No RCTs were retrieved.
Potential biases in the review process
The authors are not aware of any potential biases in the review process
Agreements and disagreements with other studies or reviews
To the authors' knowledge no other systematic reviews have been completed in this area
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Despite the large numbers of people receiving botulinum toxin for UOS dysfunction, there is no strong evidence to support this approach. This lack of evidence is both from a clinical and a quality of life viewpoint. Given the potential safety issues associated with this intervention, stronger evidence is urgently required to support its clinical use.
Implications for research
Currently, no evidence is available to support the routine use of botulinum toxin to treat neurogenic dysphagia. Methodologically sound randomised control trials are urgently required in order to verify its safety and clinical value across various adult neurogenic groups and to determine optimal candidacy and protocols.
Randomised control trials should address numerous methodological design issues lacking in clinical studies to date. These include:
• · examination of homogeneous clinical groups within studies using clear inclusion and exclusion criteria which might confound data (e.g. presence of tracheostomy)
• · precise information regarding the clinical presentation of participants including staging/severity of disease (e.g. time post acute stroke; stage of Parkinson's disease)
• · clear description of the administration of botulinum toxin protocol within studies and consistency of protocols within studies (i.e. administrator, botox type and commercial brand, methods of dilution if used, dosage, syringe type and size used, injection site; delivery method-endoscopic or transcutaneous, preparation of patient for procedure with information on whether general anaesthesia or conscious sedation was used.
• · Use of objective and reliable evaluation tools that can reliably capture UOS opening during swallowing (i.e. videofluoroscopy or FEES)
• Psychometrically sound outcome measures must be used. The use of parameters that examine not only changes in the swallow function but the satisfaction of patient and carerr with the intervention must also be measured. The impact of the intervention on quality of life and psychological well-being should be included in studies to examine the wider impact of intervention.
• · Rigorous method of randomisation • · Sufficient trial numbers with adequate matching of control and clinical groups • · blinding of researchers and participants to the intervention received (i.e. placebo or botox)
• · evaluation post intervention at multiple time frames (i.e. immediate, medium term and long term intervals).
• If crossover trials are used then the washout period for botulinum toxin used must first be established
• The presence and severity of all adverse effects of botulinum toxin should be reported to enable investigators to calculate the number needed to harm, and so that patients, families and carers can make informed decisions on the risks and side-effects associated with the intervention. • Studies examining the number of botulinum toxin injections, and the number of repeated injections needed to maintain UOS function effectively should be undertaken. These studies should consider the washout period for these interventions and measure systematically the adverse effects of repeated botulinum toxin injections and repeated doses of medications. Measurement of the client/carer satisfaction with these interventions should be included in these studies.
• Power calculations should be performed on all studies with sufficient numbers of participants recruited into trails thus avoiding false negative conclusions.
• Data should be analysed on an 'intention to treat" basis • Confidence intervals must be calculated and reported for the results of outcomes.
• All trials should be reported according to the guidelines set out in the CONSORT statement (CONSORT 2010) Appendix 4. AMED search strategy 31. 8 and (15 or 21) and 30 30.
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